布地奈德、异丙托溴铵、博利康尼联合雾化吸入治疗小儿毛细支气管炎的效果及对临床症状的影响  

The Effect of Budesonide,Ipratropium Bromide,Briconil Combined with Atomization Inhalation in the Treatment of Children with Bronchiolitis and Its Influence on Clinical Symptoms

作　　者：于洋 YU Yang(Department of Pediatrics,People's Hospital of Lishui District,Nanjing,Jiangsu Province,211200 China)

机构地区：[1]江苏省南京市溧水区人民医院儿科,江苏南京211200

出　　处：《系统医学》2022年第4期163-166,共4页Systems Medicine

摘　　要：目的探讨布地奈德、异丙托溴铵、博利康尼联合雾化吸入治疗小儿毛细支气管炎的效果及对临床症状的影响。方法选取2018年10月—2020年10月江苏省南京市溧水区人民医院收治的97例小儿毛细支气管炎患儿作为研究对象,将其随机分为对照组(n=48)和治疗组(n=49)。对照组给予异丙托溴铵、博利康尼联合雾化吸入治疗,治疗组给予布地奈德、异丙托溴铵、博利康尼联合雾化吸入治疗。对比两组临床疗效、临床症状消失时间、气道阻力(Reff)、功能残气量(FRC)、吸气时间占呼吸时间比(tI/tT)及不良反应发生情况。结果治疗组临床总有效率为95.92%,明显高于对照组的81.25%,差异有统计学意义(χ^(2)=5.189,P=0.023);治疗组肺部湿啰音、喘憋、咳嗽等症状消失时间明显短于对照组,差异有统计学意义(t=8.152、7.326、11.509,P<0.001);治疗后,两组Reff、FRC均有所下降,且治疗组均明显低于对照组,差异有统计学意义(t=5.660、4.528,P<0.001),两组tI/tT略有所上升,差异无统计学意义(t=0.048,P=0.962);治疗组与对照组不良反应发生率分别为4.08%和2.08%,两组比较差异无统计学意义(χ^(2)=0.000,P=1.000)。结论布地奈德、异丙托溴铵、博利康尼联合雾化吸入治疗小儿毛细支气管炎,其临床效果显著,可缩短临床症状缓解时间,改善肺部功能,且不会引发严重的不良反应,具有一定的安全性,值得推广。Objective To investigate the effect of budesonide,ipratropium bromide,briconil combined with atomization inhalation in the treatment of children with bronchiolitis and its influence on clinical symptoms.Methods A total of 97 children with bronchiolitis who were admitted to the People's Hospital of Lishui District,Nanjing City,Jiangsu Province from October 2018 to October 2020 were selected as the research objects,and they were randomly divided into the control group(n=48)and the treatment group(n=49).The control group was given ipratropium bromide,briconid combined with aerosol inhalation therapy,the treatment group was given budesonide,ipratropium bromide,briconid combined with aerosol inhalation therapy.The clinical efficacy of the two groups was compared,time to disappearance of clinical symptoms,airway resistance(Reff),functional residual capacity(FRC),ratio of inspiratory time to breathing time(tI/tT)and occurrence of adverse reactions.Results The total clinical effective rate of the treatment group was 95.92%,which was significantly higher than that of the control group 81.25%,the difference was statistically significant(χ^(2)=5.189,P=0.023).The disappearance time of pulmonary wet rales,wheezing,cough and other symptoms in the treatment group was significantly shorter than that in the control group,the difference was statistically significant(t=8.152,7.326,11.509,P<0.001).After treatment,Reff and FRC in the two groups decreased,and the treatment group was significantly lower than the control group,the difference was statistically significant(t=5.660,4.528,P<0.001),and the tI/tT of the two groups increased slightly,the difference was not statistically significant(t=0.048,P=0.962);the incidence of adverse reactions in the treatment group and the control group were 4.08%and 2.08%,respectively,the difference was not statistically significant(χ^(2)=0.000,P=1.000).Conclusion The combination of budesonide,ipratropium bromide and briconil in the treatment of children with bronchiolitis has a significant clinical

关 键 词：布地奈德 异丙托溴铵 博利康尼 雾化吸入 小儿毛细支气管炎 临床症状 

分 类 号：R725[医药卫生—儿科]